Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells

All current regimens for treating ovarian cancer center around carboplatin as standard first line. The HSP90 inhibitor ganetespib is currently being assessed in advanced clinical oncology trials. Thus, we tested the combined effects of ganetespib and carboplatin on a panel of 15 human ovarian cancer...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cell Death Differ
Egile Nagusiak: Kramer, Daniela, Stark, Nadine, Schulz-Heddergott, Ramona, Erytch, Norman, Edmunds, Shelley, Roßmann, Laura, Bastians, Holger, Concin, Nicole, Moll, Ute M, Dobbelstein, Matthias
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group 2017
Gaiak:
Original Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5299713/
https://ncbi.nlm.nih.gov/pubmed/27834954
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cdd.2016.124
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak